JP2025508308A - 神経変性性または神経学的な疾患または障害に対する顆粒球マクロファージコロニー刺激因子ベースの治療 - Google Patents

神経変性性または神経学的な疾患または障害に対する顆粒球マクロファージコロニー刺激因子ベースの治療 Download PDF

Info

Publication number
JP2025508308A
JP2025508308A JP2024542110A JP2024542110A JP2025508308A JP 2025508308 A JP2025508308 A JP 2025508308A JP 2024542110 A JP2024542110 A JP 2024542110A JP 2024542110 A JP2024542110 A JP 2024542110A JP 2025508308 A JP2025508308 A JP 2025508308A
Authority
JP
Japan
Prior art keywords
csf
patient
expression
treatment
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508308A5 (enExample
Inventor
ロック、エドウィン
ジョシー、イラ
ボイド、ティモシー
Original Assignee
パートナー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パートナー セラピューティクス インコーポレイテッド filed Critical パートナー セラピューティクス インコーポレイテッド
Publication of JP2025508308A publication Critical patent/JP2025508308A/ja
Publication of JP2025508308A5 publication Critical patent/JP2025508308A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024542110A 2022-02-11 2023-02-10 神経変性性または神経学的な疾患または障害に対する顆粒球マクロファージコロニー刺激因子ベースの治療 Pending JP2025508308A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309220P 2022-02-11 2022-02-11
US63/309,220 2022-02-11
PCT/US2023/062374 WO2023154855A2 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Publications (2)

Publication Number Publication Date
JP2025508308A true JP2025508308A (ja) 2025-03-26
JP2025508308A5 JP2025508308A5 (enExample) 2026-02-20

Family

ID=87565120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542110A Pending JP2025508308A (ja) 2022-02-11 2023-02-10 神経変性性または神経学的な疾患または障害に対する顆粒球マクロファージコロニー刺激因子ベースの治療

Country Status (8)

Country Link
US (1) US20250134959A1 (enExample)
EP (1) EP4475874A4 (enExample)
JP (1) JP2025508308A (enExample)
KR (1) KR20240147980A (enExample)
CN (1) CN118660715A (enExample)
AU (1) AU2023219770A1 (enExample)
CA (1) CA3242855A1 (enExample)
WO (1) WO2023154855A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235795A2 (en) * 2022-06-01 2023-12-07 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
WO2025168003A1 (zh) * 2024-02-06 2025-08-14 上海市第四人民医院 一种治疗神经退行性疾病的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2017185085A1 (en) * 2016-04-22 2017-10-26 Board Of Regents Of The University Of Nebraska Biomarkers for monitoring immune transformation
EP4103618A4 (en) * 2020-02-12 2024-05-01 The Scripps Research Institute LONG-ACTING GM-CSF AND METHODS OF USE

Also Published As

Publication number Publication date
CA3242855A1 (en) 2023-08-17
WO2023154855A2 (en) 2023-08-17
AU2023219770A1 (en) 2024-08-22
CN118660715A (zh) 2024-09-17
US20250134959A1 (en) 2025-05-01
EP4475874A4 (en) 2026-05-13
KR20240147980A (ko) 2024-10-10
EP4475874A2 (en) 2024-12-18
WO2023154855A3 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
US12297287B2 (en) CD14 antagonist antibodies for treating neurodegenerative diseases
Harari et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis
Olsson et al. Neuronal interferon‐γ immunoreactive molecule: Bioactivities and purification
CN113286816B (zh) 用于α-1-抗胰蛋白酶病症的组合物和方法
JP7678802B2 (ja) Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
CA2743394C (en) Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
US20180228869A1 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
ITRM940794A1 (it) Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
US20250134959A1 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
KR19980064719A (ko) 인터로이킨-18-수용체 단백질
JPH06315394A (ja) Ｔｎｆリガンド
JP2022513008A (ja) 融合タンパク質およびその使用
CN114230663A (zh) TrkA的抗体及其应用
HRP20030215A2 (en) Chemokine mutants in the tratment of multiple sclerosis
EP3917958A1 (en) Treatment of neurotoxicity and / or cytokine release syndrome
CN118043672A (zh) 帕金森病的生物标志物
US20090191191A1 (en) Methods for the Modulation of IL-13
US20240361339A1 (en) Biomarkers for parkinson's disease
EP1740199B1 (en) Il6r/il6 chimera for therapy of chemotherapy-induced peripheral neuropathy
WO2023235795A2 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
WO2016035052A1 (en) Anti-nerve growth factor antibodies for treating itching
AU2011203356B2 (en) IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
CA2938366A1 (en) New pharmaceutical compositions and their use for the treatment of autoimmune disorders

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260210